持续一致的安全性_马康华.pptVIP

XIENCE V N=2458 TAXUS N=1229 Stent thrombosis (%) 0.42% 1.23% p=0.008 支架血栓 (ARC定义 确诊的 或 可能的) 早期 (0 – 30 days) 晚期 (30 days – 1 year) 极晚期 (1 year) Rates (%) are Kaplan-Meier estimates. AP2933809-INT Rev. A SPIRIT IV 结论 在大规模、前瞻性、多中心、随机对照研究SPIRIT IV中，依维莫司药物支架 XIENCE V优于紫杉醇药物支架TAXUS Express的1年期出色结果继续保持至2年。 随访2年时，XIENCE V组与TAXUS组相比： TLF风险降低30%(差值为3.0%) ID-TLR风险降低34%(差值为2.4%) MI风险降低36%(差值为1.4%) 支架血栓(ARC定义)风险降低64%(差值为0.8%) 非糖尿病患者中，TLF风险降低39%(差值为3.8%)；糖尿病患者中，TLF无显著性差异 各复杂病变亚组(包括多病变、长病变和小血管病变)中的TLF一致降低 AP2933809-INT Rev. A 谢谢！ QA * * * XIENCE has been researched extensively across multiple trials and thousands of patients. * “一项又一项的研究，坚实的循证医学证据”又在这张幻灯片中得到了体现。尽管RCT是临床研究中的金标准，注册登记研究提供了真实世界人群中的数据。在来自全球超过10,000多名患者的4个注册登记研究中， Xience V显示出了持续一致的低水平的血栓发生率（1%）。 * * * * * * * * * * * * * * * * * * * * * * SE2926383 REV A Information contained herein intended for healthcare professionals outside the U.S. and Japan only AP2933809-INT Rev. A COMPANY CONFIDENTIAL. Internal use only. Not to be reproduced, distributed or excerpted. PERSEUS Primary Endpoint ? Dean Kereiakes ? ACC/i2 Late Breaking Trial ? Monday, March 15, 2010, 11:06 am Slide * AP2933809-INT Rev. A COMPANY CONFIDENTIAL. Internal use only. Not to be reproduced, distributed or excerpted. NEVO? Sirolimus-eluting Coronary Stent is an investigational device exclusively for clinical investigations and is not approved for sale in any market NEVO? Sirolimus-eluting Coronary Stent is an investigational device exclusively for clinical investigations and is not approved for sale in any market AP2933809-INT Rev. A COMPANY CONFIDENTIAL. Internal use only. Not to be reproduced, distributed or excerpted. NEVO? Sirolimus-eluting Coronary Stent is an investigational device exclusively for clinical investigations and is not approved for sale in any market SE2932341 Rev. A Slide * PERSEUS Primary Endpoint ? Dean Kereiakes ? ACC/i2 Late Breaking Trial ? Monday, March 15, 2010, 11:06 am AP2933809-INT Rev. A COMPANY C